Esperion Therapeutics Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 2 sell ratings, 5 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Esperion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View analyst ratings for Esperion Therapeutics or view top-rated stocks.

Wall Street analysts have given Esperion Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Esperion Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Esperion Therapeutics.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its quarterly earnings results on Tuesday, August, 3rd. The biopharmaceutical company reported ($1.67) EPS for the quarter, topping the Zacks' consensus estimate of ($1.82) by $0.15. The biopharmaceutical company earned $40.70 million during the quarter, compared to the consensus estimate of $42.16 million. The firm's revenue for the quarter was down 80.8% compared to the same quarter last year. During the same period last year, the firm earned $4.32 EPS.
View Esperion Therapeutics' earnings history.

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ESPR stock has decreased by 71.2% and is now trading at $12.36.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued 1-year target prices for Esperion Therapeutics' stock. Their forecasts range from $17.00 to $114.00. On average, they anticipate Esperion Therapeutics' share price to reach $45.09 in the next year. This suggests a possible upside of 264.8% from the stock's current price.
View analysts' price targets for Esperion Therapeutics or view top-rated stocks among Wall Street analysts.

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

Some companies that are related to Esperion Therapeutics include Zealand Pharma A/S (ZEAL), Vectura Group (VEGPF), Y-mAbs Therapeutics (YMAB), Kura Oncology (KURA), Travere Therapeutics (TVTX), COMPASS Pathways (CMPS), Madrigal Pharmaceuticals (MDGL), CytoDyn (CYDY), Kronos Bio (KRON), PMV Pharmaceuticals (PMVP), MacroGenics (MGNX), Avid Bioservices (CDMO), Heron Therapeutics (HRTX), Fulcrum Therapeutics (FULC) and ChemoCentryx (CCXI).
View all of ESPR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), The Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Esperion Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Bellevue Group AG (15.98%), Wasatch Advisors Inc. (13.32%), Meditor Group Ltd (10.00%), Vanguard Group Inc. (8.13%), State Street Corp (7.96%) and BlackRock Inc. (7.37%). Company insiders that own Esperion Therapeutics stock include Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics.

ESPR stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., Millennium Management LLC, Jefferies Group LLC, Jefferies Group LLC, JPMorgan Chase & Co., Nuveen Asset Management LLC, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for Esperion Therapeutics or view top insider-selling stocks.

ESPR stock was acquired by a variety of institutional investors in the last quarter, including Bellevue Group AG, Citadel Advisors LLC, Morgan Stanley, Morgan Stanley, Marshall Wace LLP, Marshall Wace LLP, Meditor Group Ltd, and State Street Corp. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben.
View insider buying and selling activity for Esperion Therapeutics or or view top insider-buying stocks.

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ESPR stock can currently be purchased for approximately $12.36.

Esperion Therapeutics has a market capitalization of $349.50 million and generates $227.55 million in revenue each year. The biopharmaceutical company earns $-143,550,000.00 in net income (profit) each year or ($5.23) on an earnings per share basis.

Esperion Therapeutics employs 479 workers across the globe.

The official website for Esperion Therapeutics is www.esperion.com.

Esperion Therapeutics is headquartered at 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108.

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at [email protected].